Get the latest news, insights, and market updates on CRMD (CorMedix Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Guidance And Revamping Its Leadership Structure
In early January 2026, CorMedix Inc. announced 2026 revenue guidance of US$300 million to US$320 million and significant leadership changes, including CEO Joseph Todisco becoming Chairman and the appointment of industry veteran Mike Seckler as EVP & Chief Commercial Officer. The combination of a lower revenue outlook tied to upcoming DefenCath reimbursement changes and a tighter CEO–Chairman structure, alongside a new commercial leader, points to a company recalibrating both its financial... Jan 9, 2026 - $CRMD
How Recent Q3 Updates Are Shaping The CorMedix (CRMD) Investment Story
Why the CorMedix Price Targets Are Holding Steady CorMedix is back in focus after preliminary Q3 sales and fresh Street commentary, yet the core price targets have stayed as they are, with a US$19 fair value estimate and a US$14 target reiterated rather than reset. Supportive views lean on what bullish analysts describe as "robust" preliminary Q3 sales and improving visibility on operating synergies, while more cautious voices point to execution risk and the gap between the fair value... Jan 9, 2026 - $CRMD
Are Investors Undervaluing CorMedix (CRMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Jan 9, 2026 - $CRMD
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST. 44th Annual Jan 9, 2026 - $CRMD
A Look At CorMedix (CRMD) Valuation After 2026 Guidance Shift And Executive Changes
What triggered fresh attention on CorMedix stock? CorMedix (CRMD) has drawn fresh investor attention after issuing 2026 revenue guidance of US$300 million to US$320 million and outlining expected reimbursement changes for DefenCath, along with key leadership shifts at the top of the company. See our latest analysis for CorMedix. Despite the guidance update and leadership changes, the 1-year total shareholder return of 3.33% contrasts with a much stronger 3-year total shareholder return of... Jan 8, 2026 - $CRMD
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $148 million ‒ BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases Jan 8, 2026 - $CRMD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple